Velocity is the world's leading integrated site organization.
Sponsors and CROs trust Velocity to deliver high-quality clinical trial data and patient care with unprecedented efficiency.
Simplify everything from site selection to study close-out
Velocity unifies operational processes to provide world-class sites, reliable enrollment, and predictably high performance for your trials.
News
Positive Topline Results Announced for ACCESS Studies for Aleniglipron (Oral GLP-1 RA)
Congratulations to the Structure Therapeutics team for announcing positive topline data from its ACCESS clinical program for aleniglipron, an oral GLP-1 receptor agonist. Julio Rosenstock, MD, Chair of the ACCESS … Read more
Henrik Watz, MD, PhD, Authors Results for the First Clinical Trial of Glasmacinal (EP395) in COPD Patients
Henrik Watz, MD, PhD, is the chief investigator and author of trial results for EpiEndo’s clinical trial of glasmacinal (EP395). Results indicated that glasmacinal reduced neutrophilic inflammation in COPD patients … Read more
An Interview With Omaha’s Fritz Raiser, DO, on Vaccines, Obesity Care, and Bringing Research Back to the ER
When you first meet Fritz Raiser, DO, you could be forgiven for thinking he was on holiday. There’s a quiet ease about him, a calm confidence that feels almost out … Read more
Stanley Hsia, MD, Presents Phase 2 Trial Results for Mazdutide (GLP-1/Glucagon Dual Agonist)
At ObesityWeek in Atlanta, Stanley Hsia, MD, presented results from a Phase 2 Eli Lilly/Innovent Biologics study of mazdutide, a once-weekly injectable GLP-1/glucagon dual agonist. The study demonstrated dose-dependent weight … Read more